Expression of NOX2 protein in neutrophils of patients with ALS

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1562313 since 2016-05-24T14:35:58Z

Publisher:
Neurinox Consortium

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Expression of NOX2 protein in neutrophils of patients with ALS

De Marco G¹, Lomartire A¹, Casale F¹, Marrali G¹, Cammarosano S¹, Ilardi A¹, Canosa A¹, Moglia C¹, Calvo A¹, Rinaudo MT², Chiò A¹

¹Rita Levi Montalcini’ Department of Neuroscience, ALS Centre, University of Torino, Via Cherasco 15, 10126, Turin, Italy
²Department of Oncology, University of Torino, Via Michelangelo 27bis, 10125, Turin, Italy

Oxidative stress, more precisely the damage caused by an abnormal production of reactive oxygen species (ROS), is a key mechanism in ALS pathogenesis. NADPH oxidases are a family of enzymes responsible for the production of ROS. In our previous study, an increased survival of ALS-affected individuals has been related to low activity of NADPH oxidase-2 (NOX2) in their neutrophils (1). Based on this finding, this work aimed to evaluate the protein levels of NOX2 in neutrophils of patients affected by ALS, in order to verify a possible correlation between levels and activity.

The analysis was performed in a cohort of 40 subjects using Western immunoblot technique. The attention was mainly focused on ALS patients carrying mutations of copper-zinc superoxide dismutase-1 (SOD1) gene, since mutations of SOD1 are referred to alter NOX2 activity (2).

(1) Marrali G et al. NADPH oxidase (NOX2) activity is a modifier of survival in ALS. J. Neurol. 2014